Quick Answer: Foreign nationals can invest directly in Israeli startups without general regulatory approval — Israel has no unified foreign investment screening regime for most tech sectors. Key legal points for foreign investors include understanding the Angels Law (*Hok HaMal'akhim*) tax incentives, the correct deal structure under the Companies Law 1999, the capital gains exemption for non-residents, and when a national security review may apply.

Israel has earned its global reputation as the "Startup Nation" — a country of nine million people that consistently ranks among the world's leading hubs for venture-backed technology companies, with more NASDAQ-listed companies than any country outside the United States and China. For a foreign investor — whether an individual angel, a family office, or a venture fund based in North America, Europe, or Asia — the Israeli startup ecosystem offers access to deep technological talent, substantial government-backed R&D, and a well-established exit market.

What many foreign investors do not realise is how accessible the Israeli market actually is from a legal standpoint. Unlike investing in the United States (where CFIUS review applies to many technology transactions) or in several EU member states (where sector-specific FDI screening has expanded sharply since 2020), most investments in Israeli startups require no government notification and no prior approval. The legal process is driven entirely by private contract and standard Israeli company law. This guide explains the legal framework that governs foreign investment in Israeli startups, from deal structures and tax considerations to the specific circumstances where additional review applies.

1. Israel's Open Investment Framework

Israel does not have a general, unified foreign direct investment screening mechanism analogous to CFIUS in the United States. For the broad range of Israeli technology startups — covering software, SaaS, medical devices, fintech, cybersecurity, agri-tech, and clean energy — a foreign investor can acquire equity in an Israeli company without any prior governmental notification or approval.

The foundational legislation governing Israeli companies is the Companies Law 1999 (*Hok HaHevrot, 5759–1999*), which treats foreign and domestic shareholders equally in virtually all respects. Under this framework:

  • Foreign individuals and foreign entities may hold shares directly in Israeli private companies — no Israeli subsidiary or local partner is required.
  • There is no general cap on the percentage of a company a foreigner may own; 100% foreign ownership is legally permissible in most sectors.
  • Dividends and sale proceeds may be repatriated abroad, subject to applicable tax withholding rules.
  • Foreign shareholders have the same statutory voting rights, information rights, and minority protections as Israeli shareholders.

The only significant exception to this open framework is sector-specific licensing: investments in regulated industries such as banking, insurance, telecommunications, and certain defense-adjacent businesses may trigger sector regulator review. For pure-technology startups without regulated licenses, this exception rarely applies. When it does, your Israeli counsel will identify it during due diligence.

2. The Angels Law and Tax Incentives for Foreign Investors

One of the most distinctive features of Israeli early-stage investment is the Angels Law (*Hok HaMal'akhim*), enacted by the Knesset to encourage early-stage private investment in Israeli research and development companies. Understanding how it works — and where it does and does not benefit foreign investors — is essential before structuring your deal.

Under the Angels Law, an investor who makes a qualifying investment in a qualifying R&D company may deduct the invested amount against their Israeli taxable income in the tax year the investment is made. The deduction effectively reduces the after-tax cost of the investment for investors who have Israeli-source income to offset.

Eligibility conditions for the company:

  • Must be an Israeli private company registered with the Israel Companies Registrar (*Rasham HaHevrot*).
  • Must be primarily engaged in R&D activity at the time of investment.
  • Must not be publicly traded.
  • Must apply for and receive a certification from the Israel Innovation Authority (*Rashut HaHidaon*) confirming qualifying status.
  • Annual revenues must not exceed a statutory threshold (verify the current limit with your advisor, as the Knesset periodically amends this figure).

What this means for foreign investors specifically: If you are not an Israeli tax resident and do not have a permanent establishment in Israel, you typically have no Israeli taxable income against which to claim the deduction. The Angels Law deduction will therefore be of limited direct benefit to most foreign angel investors investing from abroad.

However, there is a separate and often more important tax benefit for non-residents: capital gains on the sale of shares in Israeli companies are generally exempt from Israeli capital gains tax for non-Israeli residents, provided those gains are not attributable to a permanent establishment in Israel and subject to the terms of any applicable double taxation treaty. Israel has signed double taxation treaties with over 50 countries, including the United States, the United Kingdom, France, Germany, Canada, and Australia. The combination of no capital gains tax at exit and no general entry restrictions makes the Israeli market genuinely attractive from a tax perspective. Always confirm the specific position under your home country's treaty with Israel before investing.

3. Investment Structures: Equity, SAFEs, and Convertible Notes

Israeli startup investments are typically documented using one of three instruments. Each has distinct legal characteristics under Israeli law that a foreign investor should understand before signing.

Direct equity (ordinary or preferred shares)

The most straightforward structure. You purchase shares in the Israeli company, and your rights are defined by the company's Articles of Association (*takanon*) and any shareholders' agreement. Under the Companies Law 1999, share class rights may be differentiated in the articles, and preferred shareholders in Israeli startups typically receive:

  • Anti-dilution protection (broad-based weighted average is market standard).
  • Liquidation preference — the right to receive invested capital back before ordinary shareholders in a liquidation or acquisition below a certain threshold.
  • Pro-rata rights to participate in future financing rounds.
  • Information rights (quarterly management accounts, annual audited financials).
  • Tag-along rights, allowing you to sell alongside a controlling shareholder if they receive an acquisition offer.

Ensure the company's articles are updated before closing to formally reflect the new share class. An amended articles filing is required at the Israel Companies Registrar.

Convertible notes (*shtar hamara*)

Commonly used for bridge rounds and pre-seed investments, convertible notes are debt instruments that convert into equity at a future priced round or maturity event. Israeli law treats convertible notes as debt until conversion, which has implications for creditor priority if the company becomes insolvent. Key drafting points for Israeli convertible notes include:

  • Clear conversion trigger events (next equity round above a threshold, acquisition, IPO, or maturity date).
  • Valuation cap and/or conversion discount — both are common in Israeli practice.
  • Whether the note is secured (and if so, whether a charge is registered at the Registrar of Companies).
  • Interest rate — Israeli law requires that interest be stated; a zero-interest convertible note should expressly waive interest to avoid ambiguity.

SAFEs (Simple Agreements for Future Equity)

Originally developed by Y Combinator in the United States, SAFEs have become widely used in Israeli early-stage rounds over the past several years. A SAFE grants the right to receive equity at a future priced round rather than functioning as debt. Unlike a convertible note, it does not carry an interest rate or a maturity date that creates default risk. Israeli courts have not generated substantial published case law on SAFEs specifically; well-drafted conversion provisions and a clear governing-law clause are therefore especially important. Confirm that Israeli counsel has reviewed the SAFE template and adapted it where necessary for Israeli company law compliance.

4. National Security Review for Foreign Investments

In 2019, the Israeli government established an Advisory Committee for Evaluating National Security Aspects of Foreign Investments (*HaVa'adah HaYe'atzet LeHa'arakat Hihbut HaHashka'ot HaZarot*). This body, chaired by a senior official at the Prime Minister's Office, advises the relevant government minister when a proposed foreign investment may affect Israeli national security.

For most foreign investors in tech startups, this mechanism is not relevant. The committee's review is not automatic — it is triggered when regulators or sector ministries flag a specific transaction. The situations most likely to attract attention include:

  • Investment in a company that operates or provides services in critical national infrastructure (water treatment, electricity, ports, communications backbone).
  • Acquisition of control (generally above 25% of voting rights) in a company that supplies technology or services to Israeli defense or intelligence bodies.
  • Transactions involving investors from countries with which Israel has significant geopolitical sensitivities.

If you are investing in a cybersecurity company that has contracts with Israeli government agencies, a defense-tech startup, or a company operating in regulated critical infrastructure, discuss the national security review framework with your Israeli corporate attorney before executing the term sheet. In most commercial tech investments — SaaS, fintech, health tech, consumer apps, clean energy for private markets — the review simply does not apply.

5. Due Diligence Checklist Before Investing

Before wiring funds into an Israeli company, a foreign investor should conduct legal and commercial due diligence. The following categories are the minimum for any early-stage investment; later-stage investments warrant significantly more detailed review.

Corporate records

  • Certificate of incorporation (*ta'udat hitaadut*) from the Israel Companies Registrar — confirm the company is in good standing and not in dissolution proceedings.
  • Up-to-date Articles of Association reflecting all prior share issuances and class rights.
  • Full capitalisation table showing all existing shareholders, option holders, SAFEs, convertible notes, and warrants — including vesting schedules for founders and key employees.
  • Board and shareholder resolutions approving previous equity grants, the current financing round, and any material contracts.

Intellectual property

  • Confirm that all material IP is owned by the company, not by individual founders. In early-stage Israeli companies, founders sometimes develop technology before formal incorporation; assignment agreements must have been executed.
  • Review all employee and contractor IP assignment and confidentiality agreements. Under the Patent Law 1967 and general Israeli employment law, inventions made by an employee in the course of their employment belong to the employer — but the underlying assignment should still be documented.
  • If the Israel Innovation Authority has provided R&D grants, confirm that the company is compliant with the conditions attached. IIA grants typically carry obligations that limit the transfer of resulting technology outside of Israel and require prior IIA approval for certain corporate transactions including M&A and licensing.

Regulatory and compliance

  • Privacy: The Protection of Privacy Law 1981 and the 2017 Data Security Regulations apply to Israeli companies handling personal data. Review whether the company has registered as a database holder with the Israeli Privacy Protection Authority (*Rashut HaGanat HaPrivasiut*) where required.
  • Employment: Israeli employees benefit from extensive statutory protections — annual leave, severance pay under the Severance Pay Law 1963, advance notice requirements, and social insurance contributions. Review the employment agreements and confirm that accrued severance and pension contributions are properly funded.
  • Tax status: Request confirmation from the Israeli Tax Authority (*Rashut HaMisim*) that the company has no outstanding tax liabilities. A company with unpaid tax debts can create unexpected complications for investors when those debts come to light post-investment.

6. Practical Steps to Close Your Investment

The typical closing process for a foreign investor investing in an Israeli startup follows these stages:

  1. Term sheet / Letter of Intent: A non-binding document setting out the key economic and governance terms — valuation, instrument type, pro-rata rights, board seats (if any), and any conditions to closing. In Israeli practice this is sometimes called a *memorandum of understanding* (*haskamah le'kavanat*). Negotiate this carefully: while non-binding, term sheets set expectations that are difficult to walk back at the agreement stage.
  2. Due diligence: Typically two to four weeks for an early-stage deal; six to eight weeks or more for a growth-stage round. Your Israeli counsel should lead the legal review; request parallel financial and technical due diligence as appropriate.
  3. Investment agreement: The binding agreement governing the transaction — a Share Purchase Agreement for equity deals, a Note Purchase Agreement for convertible notes, or a SAFE. If other investors are participating in the same round, a co-investment agreement or an amended and restated Shareholders' Agreement will typically be executed simultaneously.
  4. Companies Registrar filings: Following closing, the company must file updated shareholder registry information and the resolutions authorising the share issuance with the Israel Companies Registrar (*Rasham HaHevrot*) within the statutory deadline. These filings are in Hebrew; your Israeli counsel handles them as part of the closing process.
  5. Wire transfer and AML compliance: Israeli banks are subject to Anti-Money Laundering regulations under the Prohibition on Money Laundering Law 2000. The company's bank will typically require source-of-funds documentation from foreign investors before accepting the transfer. Prepare bank statements, corporate formation documents, and a brief explanation of the source of investment funds.
  6. Share confirmation: Upon completion of the Registrar filings, you should receive written confirmation of your position on the company's share register. Physical share certificates are less common in Israeli practice than electronic register entries, but a written confirmation should always be obtained.

One practical note that surprises some foreign investors: Israeli company law does not require notarization of investment agreements for most private transactions. However, certain documents intended for use before Israeli government bodies — powers of attorney, for example — may require apostille authentication if executed abroad. Your Israeli attorney will flag this if it applies to your specific transaction.

An Australian family office invested USD 750,000 in a Tel Aviv health-tech startup via a SAFE agreement in April 2023, using a US-format Y Combinator SAFE template that the company's founders had adapted. The following year, when the company raised a Series A and the SAFEs converted to equity, the Israeli Tax Authority issued an assessment for NIS 130,000 in withholding tax — the ITA's position being that the SAFE had been treated as equity from the date of issuance and that the conversion triggered a taxable event under Israeli domestic law for non-resident investors in certain circumstances. Because no pre-ruling had been sought from the ITA before the investment and the SAFE's governing-law clause specified Israeli law without any tax treatment election, the family office had no clear contractual basis to shift this liability to the company. After negotiations spanning four months, the parties agreed to split the tax liability, with the company absorbing NIS 75,000. The lesson: the Israeli tax treatment of SAFEs issued by Israeli companies is unsettled, and a pre-ruling request to the ITA costs approximately NIS 5,000–12,000 in legal fees — a small fraction of the exposure that arises from skipping the step.

In Practice: Israeli banks require source-of-funds documentation for incoming wire transfers from foreign investors — this means recent bank statements, a letter from the investor's own bank confirming the account relationship, and sometimes a source-of-wealth declaration. Banks routinely freeze unidentified incoming transfers pending clarification. Prepare this documentation before the wire is sent, not after. An investor who wires funds without coordinating with the company's bank risks the transfer being held for weeks — delaying closing and creating complications for the company's post-investment activities.
In Practice: SAFEs issued by Israeli companies are treated differently from US SAFEs for Israeli tax purposes. The Israel Tax Authority has indicated that SAFEs may be treated as equity instruments — rather than deferred obligations — at the time of investment, with potential withholding tax implications for certain non-resident investors. This area of the law remains unsettled. Foreign investors using SAFEs in Israeli companies should obtain a pre-ruling from the ITA confirming the tax treatment before closing, rather than discovering the issue when the SAFE converts at the next round.